1 JLM.Oral and iv formulations of gatifoxacin cleared for US.marke t.Am J Health-Syst Pharm, 2000;57:204
2 Hosaka M, Kinoshita S, Toyama A, et al.Antibacterial proper ties of AM-1155, a new 8-methox y quinolone.J Antimicrob Chemther, 1995;36:293
3 Tomioka H, Saito H, Sato K.Comparative antimycobacterial activities of the newly sy nthesized quinolone AM-1155, sparflo xacin and oflo xacin. Antimicrob Agents Chemother, 1993;37:1259
4 潘志平.氟喹诺酮类抗菌剂gatiflo xacin.药学进展, 2000;24:51
5 Takei M, Fukuda H, Yasue T, et al.Inhibitory activities of gatiflox acin (AM-1155), a newly dev elo ped fluoroquinolone, against bacterial and mammalian ty pe Ⅱ topoisomerase.Antimicro Agents Chemother, 1998;42:2678
6 Wakabayshi E, Mitsuhashi S.In vitro antibacterial activitiy of AM-1155, a novel 6-fluoro-8-metho xy quinolone. Antimicrob Agents Chemother, 1994;38:594
7 Fukuda H, Hori S, Hiramatsu K.Antibacterial activity of gatiflox acin (AM-1155, CG5501, BMS-206584), a newly developed fluo roquinolone, against sequentially acquired quinolone-resistants mutants and the norA transformant of staphylococcus aureus. Antimicrob Agents Chemother, 1998;42:1917
8 Deg uchi T, Yasuda M, Nakano M, et al.Comparision of in vitro antimicrobial activity o f AM-1155 with those of tosuflox acin and fleroxacin against clinicaliso lates of neisseria gonorrhoeae harbo ring quinolone resistance alterations in GyrA and ParC.Chemotherapy, 1997;43:239
9 Appelbaum PC.Quinolone activity against anaerobes. Drugs, 1999;58 (suppl 2):60
10 Ednie LM, Jacobs M, Appelaum PC.Activities of ga tifloxacin compared to those of seven other agents against anaerobic org anisms. Antimicrob Agents Chemother, 1998;42:2459
11 Miyashita N, Niki Y, Kishimono T, et al.In vitro and in vivo activities of AM-1155, a new fluoroquinolo ne, ag ainst Chlamy dia spp.Antimicrob Agents Chemother, 1997;41:1331
12 Hosaka M, Yasue T, Fukuda H, et al.In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-me thoxy quinolone.Antimicrob Agents Chenother, 1992;36:2108
13 Nakashima M, Uematsu T, Kosuge K, et al.Single-and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.Antimicrob Agents Chemother, 1995;39 (12):2635
14 赵树清, 王金生.新型氟喹诺酮抗菌剂——AM-1155. 中国医药情报, 1996;2:249
15 Perry CM, Balfour JAB, Lamb HM.Gatiflox acin.Drugs, 1999;58:683
16 李眉, 左晓春, 赵明.抗革兰阳性耐药菌感染药物的研究 进展.中国临床药理学杂志, 1999;15:450
17 Anon.Gatifloxacin AM-1155.drugs Fut, 1998;23:330
18 周伟澄, 张秀平.氟喹诺酮药物研究新进展.中国新药 杂志, 2000;9:667
19 许铁男.新喹诺酮类抗菌剂AM1155.国外医药抗生素 分册, 1998;19:302
20 Lober S, Ziege S, Rau M, et al.Pharmcokinetics of gatifox acin and interaction with an antacid containing aluminum and magnesium.Antimicrob Agents Chemother, 1999;43:1067
21 Stahlberg HJ, Gohler K, Guillane M, et al.Effects of gatiflox acin (GTX) on the pharmacokinetics of theo phy line in heathly y oung volunteers [abstract]. J Antimicrob Chemther.1999;44 (suppl A):136 |
